Celyad’s CAR T leads to leukemia-free state in AML patient

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said a patient with acute myelogenous leukemia (AML) achieved a morphologic leukemia-free state (MLFS) after receiving the company's chimeric antigen receptor (CAR) T cell therapy (CAR-T NKG2D, CAR-T NKR-2) in the Phase I THINK trial. The company defined an MLFS as achieving bone marrow blasts of <5%, absence of blasts with Auer rods, and absence of extramedullary disease, with no hematologic recovery required.

Celyad said the response is the first time a relapsed, refractory AML patient has achieved an MLFS with a gene-engineered T cell therapy without prior pre-conditioning chemotherapy. The AML patient received 3x10⁸ CYAD-01 T cells every 2 weeks for a total of 3 infusions...